St. Jude Medical, a medical device company, has gained FDA clearance for the Amplatzer Vascular Plug 4 (AVP 4) for use in transcatheter embolisation procedures within the peripheral vasculature.
The AVP 4 device, which is delivered using a standard diagnostic catheter, allows physicians to reroute blood flow by blocking abnormal vessels using vascular plug technology.
The University of Minnesota Medical Center spokesperson, Jafar Golzarian, said the Amplatzer Vascular Plugs have been beneficial in precisely targeting specific vessels for embolisation.
"With the Amplatzer Vascular Plug 4, we now have the ability to use a diagnostic catheter to deliver the device, which means that patients in need of embolisation of smaller, more tortuous vessels, can benefit from this technology," Golzarian added.
Prior to deployment, the AVP 4 may be recaptured and repositioned to provide full cross-sectional vessel coverage.
The pressure on malformed, weakened or leaking blood vessels is lessened by vascular occlusion, thereby reducing blood supply to benign or malignant tumours.
Placing numerous individually threaded coils through a catheter and packing them together to block the blood flow is the current standard of care for vascular occlusion.
The St. Jude Medical cardiovascular division president, Frank Callaghan, said: "This technology simplifies the peripheral embolisation procedure for physicians by eliminating the need for catheter exchanges and blocking or redirecting blood flow through the peripheral vessels in a more efficient manner than with surgical clips or embolic coils."
The Amplatzer Vascular Plug 4 won CE Mark approval in July 2009.